The Solution For Asbestos Exposure Finally Found, Stopped Due To Trial
The Solution For Asbestos Exposure Finally Found, Stopped Due To Trial: Asbestos exposure has claimed a lot of lives and is still a serious health hazard. From asbestosis to lung cancer and mesothelioma; asbestos exposure can prove fatal in severe cases. Mesothelioma is the most aggressive form of cancer that develops in the lining of lungs.
What’s worse is that it has no definitive cure as yet. That said, there is a silver lining and scientists are on the verge of finding a cure as the ONCOS-102 mesothelioma trial moves forward.
The Solution For Asbestos Exposure Finally Found, Stopped Due To Trial
What is ONCOS-102?
ONCOS-102 is an immunotherapy vaccine which is developed by a Scandinavian pharmaceutical company. It is a scientifically engineered adenovirus that can activate the patient’s immune system to selectively target cancer cells. The results are encouraging and the scientists are very optimistic. For the trial, the vaccine is given in a combination with chemotherapy.
The ONCOS-102 Trial
Here are a few salient features of this trial.
- Patients with an inoperable disease are selected for this trial.
- Patients will undergo treatment for five months and there will be a total of 20 patients in the experimental group and 10 patients in the control group.
- Patients will be injected with ONCOS-102 directly into pleural tumor lesions.
- The main objective of this trial is to determine the overall immune activation and response of the patient when ONCOS-102 is injected, in comparison with the standard chemotherapy regimen.
- Over-all survival rate will also be measured in this trial.
- The clinical responses observed so far in safety lead-in cohort of this trial have been very encouraging and promising. Scientists believe that the future of fighting cancer lies in immunotherapy.
ONCOS-102 Trial and Its Side-effects
As the ONCOS-102 mesothelioma trial moves forward, scientists and investigators are encouraged as the six-patient cohort has not shown any side-effects except for a mild flu-like illness. This was expected as this immune-vaccine is an adenovirus derivative.
A Previous Trial Has Been Successful, too!
A randomized trial was conducted in Finland which proved to be quiet encouraging with minimal side-effects. This trial involved patients with solid tumors who were no longer responding to standard chemotherapy.
For More Information & Videos Subscribe To Our YouTube Channel